AAPL 186.61 +0.12 (+0.06%)MSFT 126.9 +0.03 (+0.02%)FB 184.76 +0.03 (+0.02%)ZNGA 6.17 0 (+0.08%)NVDA 155.05 -0.2 (-0.13%)WBA 52.73 +0.06 (+0.11%)GOOG 1148.79 -1.09 (-0.09%)PIH 5.7 -0.12 (-2.06%)
AAPL 186.61 +0.12 (+0.06%)MSFT 126.9 +0.03 (+0.02%)FB 184.76 +0.03 (+0.02%)ZNGA 6.17 0 (+0.08%)NVDA 155.05 -0.2 (-0.13%)WBA 52.73 +0.06 (+0.11%)GOOG 1148.79 -1.09 (-0.09%)PIH 5.7 -0.12 (-2.06%)

Financial Summary INSY Quote Insys Thera

Insys Therapeutics Inc. Quote

Insys Therapeut (INSY)

1.06 -0.03 Healthcare
Stock Performance rating :
Recommendation :
Not Available
Symbol INSY
Price 1.06
Beta 2.48
Vol Avg 634.21 K
Mkt cap 340.88 M
Shares 74
Last Div Not Available
Div Yield 0.00%
DCF Unlevered Not Available Not Available
DCF Levered Not Available Not Available
ROE Not Available Not Available
ROA Not Available Not Available
Operating Margin Not Available Not Available
Debt/Equity Not Available Not Available
P/E Not Available Not Available
P/B Not Available Not Available
All | Income Statement | Balance Sheet | Cash Flow | Retained Earnings | PPE Schedule | Intangible and Goodwill Schedule
Income Statement
Year 20142015201620172018
Revenue 222 331 242 0 0
COGS 23 29 25 21 11
GrossProfit 200 302 217 120 71
Depreciation (included in COGS) 2 5 6 0 0
StockBasedCompe (included in COGS) 15 20 22 16 12
ResearchAndDeve 33 55 74 63 58
SalesGeneralAnd 102 145 132 116 125
OperatingIncome 64 102 11 -59 -111
InterestExpense 0 0 0 0 0
OtherIncome 0 -9 -3 -158 -15
IncomeBeforeTax 64 93 8 -217 -126
ProvisionForInc 0 0 0 0 0
NetIncome 38 58 8 -228 -125
Balance Sheet
Year 20142015201620172018
CashAndCashEqui 58 80 105 32 32
ShortTermInvest 25 80 78 85 64
Cash 83 159 183 0 0
AccountReceivab 27 48 21 0 0
Inventories 35 42 22 0 0
DeferredIncomeT 8 16 23 0 0
OtherCurrentAss 0 0 0 0 0
TotalCurrentAss 151 253 231 176 126
PPE 39 50 63 83 87
AccumulatedDepr -9 -12 -20 -28 -35
NetPPE 30 38 43 55 52
EquityAndOtherI 23 43 54 47 8
Goodwill 0 0 0 0 0
IntangibleAsset 0 0 0 0 0
OtherLTAssets 3 0 5 1 6
TotalNonCurrent 64 98 125 103 66
TotalAssets 215 351 356 279 193
ShortTermDebt 0 0 0 0 0
AccountsPayable 0 0 0 0 0
TaxesPayable 0 0 0 0 0
AccruedLiabilit 0 0 0 0 0
DeferredRevenue 0 0 0 1 0
OtherCurrentLia 34 47 36 39 6
TotalCurrentLia 46 89 79 207 107
Debt 0 0 0 0 0
DeferredTaxesLi 0 0 0 0 0
DeferredRevenue 0 0 0 0 0
OtherLTLiabilit 4 9 8 9 4
TotalNonCurrent 4 9 8 9 129
TotalLiabilitie 49 97 87 216 236
CommonStock 0 1 1 1 1
AdditionalPaidI 216 246 257 278 293
RetainedEarning -51 7 13 -215 -336
AccumulatedOthe 0 0 0 0 0
TotalStockholde 166 254 270 63 -43
TotalLiabilitie 215 351 356 279 193
Cash Flow Statement
Year 20142015201620172018
NetIncome 38 58 8 -228 -125
Depreciation 2 5 6 0 0
DeferredIncomeT 0 -4 -6 23 0
StockBasedCompe 15 20 22 16 12
AccountsReceiva -10 -22 27 -1 25
InventoryCS -20 -7 15 2 2
AccountsPayable 0 0 0 0 0
OtherWorkingCap 50 62 -18 127 0
OtherNonCashIte -22 -14 2 0 0
NetCashProvided 50 101 59 -61 -56
InvestmentsInPP -22 -14 -11 -17 -6
AcquisitionsNet 0 0 0 0 0
PurchasesOfInve -48 -75 -115 -132 -62
SalesMaturities 0 0 104 131 121
PurchasesOfInta 0 0 0 0 0
OtherInvestingA 0 0 0 0 0
NetCashUsedForI -70 -89 -22 -18 53
DebtIssued 0 0 0 0 0
DebtRepayment 0 0 0 0 0
CommonStockIssu 2 3 2 1 1
CommonStockRepu 0 -16 -16 0 0
DividendPaid 0 0 0 0 0
OtherFinancingA 9 10 4 5 1
NetCashProvided 33 9 -12 6 2
NetChangeInCash 13 21 25 -73 0
CashAtBeginning 45 58 80 105 32
CashAtEndOfPeri 58 80 105 32 32
Retained Earnings
Year 20142015201620172018
RetainedEarning ----517
NetIncome --38588
StockDividend --13-116-14
DividendPaid -----
RetainedEarning ---51713
Property Plant and Equipment Schedule
Year 20142015201620172018
NetPPE ---3038
DeprAnnual 0--9-3-8
CapitalExpendit 00221411
NetPPE --303843
Intangible and Goodwill Schedule
Year 20142015201620172018
intAndGW 0----
Amortization 0-7-22
NewPurchases 0--72-2
intAndGW -----
Company Profile

CEO

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ Global Market

Description

Insys Therapeutics Inc develops and commercializes drugs delivery systems targeting the oncology space. The company manufactures cannabinoid formulation, and sublingual spray drug delivery technology for the US and Europe markets.